sandostatin lar 20 mg
novartis slovakia s.r.o., slovensko - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
sandostatin lar 30 mg
novartis slovakia s.r.o., slovensko - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
oktreotid teva 30 mg
teva b.v., holandsko - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
oktreotid teva 20 mg
teva b.v., holandsko - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
oktreotid teva 10 mg
teva b.v., holandsko - oktreotid - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
mycapssa
amryt pharmaceuticals dac - octreotide acetate - akromegália - hypofýzové a hypotalamické hormóny a analógy - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
mycapssa
amryt pharmaceuticals dac - octreotide acetate - acromegaly - hinsveiflur og heilahimnubólur og hliðstæður - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
sandostatin stungulyf, lausn 100 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 100 míkróg/ml
sandostatin stungulyf, lausn 50 míkróg/ml
novartis healthcare a/s - octreotidum inn - stungulyf, lausn - 50 míkróg/ml
sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg
novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg